Cargando…
Rapid simultaneous determination of indacaterol maleate and glycopyrronium bromide in inhaler capsules using a validated stability-indicating monolithic LC method
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. A combination of indacaterol maleate with glycopyrronium bromide has recently been approved as a once-daily maintenance therapy in patients with COPD. The very low dose (μg level/capsule)...
Autores principales: | Zayed, Sahar, Belal, Fathalla |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418180/ https://www.ncbi.nlm.nih.gov/pubmed/29086816 http://dx.doi.org/10.1186/s13065-017-0264-6 |
Ejemplares similares
-
Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD
por: Prakash, Anoop, et al.
Publicado: (2015) -
Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan
por: Horita, Nobuyuki, et al.
Publicado: (2015) -
Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide
por: Ridolo, Erminia, et al.
Publicado: (2019) -
Lung Function Normalisation with Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate in Patients with Asthma
por: Chapman, Kenneth R., et al.
Publicado: (2021) -
Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients
por: Miller, David, et al.
Publicado: (2020)